News
News
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs further...
Read moreDetails
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
Longeveron Inc. (NASDAQ: LGVN) , a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced...
Read moreDetailsLongeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today...
Read moreDetails
Amesite’s CEO Ann Marie Sastry Special Guest in ARK Invest’s Podcast
Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for education, business, and government...
Read moreDetails
Strong US Jobs Data Spooks Markets: Expectations for Further Rate Hikes Loom
The US labor market has shown continued signs of resilience, as evidenced by the latest job figures.
Read moreDetails
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides – NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
SHELTON, CONNECTICUT - July 6, 2023 - NanoViricides, Inc. (NYSE American: NNVC) reports that the clinical trial of its broad-spectrum...
Read moreDetails
DSS, Inc. Announces Record and Distribution Date for Impact Biomedical Spin-Off Special Dividend
ROCHESTER, N.Y., June 26, 2023 (GLOBE NEWSWIRE) DSS, Inc. (NYSE American: DSS), a multinational company operating nine business divisions through...
Read moreDetails
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease...
Read moreDetails
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease...
Read moreDetails
Charge Enterprises Reports Record Infrastructure Backlog Surpassing $100 Million and Reaffirms Growth Strategy
Charge Enterprises, Inc. (Nasdaq: CRGE) today reported record backlog after the close of the first quarter 2023 and reaffirmed its...
Read moreDetails